Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial

Clément Dumont; Giulia Baciarello; Pierre Olivier Bosset; Pernelle Lavaud; Emeline Colomba; Christophe Massard; Yohann Loriot; Laurence Albiges; Pierre Blanchard; Alberto Bossi; Soazig Nenan; Karim Fizazi

doi:10.1016/j.clgc.2020.03.017

Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial

Clément Dumont, Giulia Baciarello, Pierre Olivier Bosset, Pernelle Lavaud, Emeline Colomba, Christophe Massard, Yohann Loriot, Laurence Albiges, Pierre Blanchard, Alberto Bossi, Soazig Nenan, Karim Fizazi

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Addition of taxane-based chemotherapy to androgen deprivation therapy improved relapse-free survival in men with high-risk localized prostate cancer; however, long-term toxicities are unknown. This longitudinal study of 78 patients from the GETUG-12 randomized trial treated at Gustave Roussy shows that additional chemotherapy with docetaxel and estramustine does not impact the restoration of androgen secretion and related side effects after castration discontinuation.

Original language	English
Pages (from-to)	444-451
Number of pages	8
Journal	Clinical Genitourinary Cancer
Volume	18
Issue number	6
DOIs	https://doi.org/10.1016/j.clgc.2020.03.017
Publication status	Published - 1 Dec 2020

Keywords

Cardiovascular events
Erectile dysfunction
Libido
Neoadjuvant chemotherapy
Testosterone

Access to Document

10.1016/j.clgc.2020.03.017

Cite this

Dumont, C., Baciarello, G., Bosset, P. O., Lavaud, P., Colomba, E., Massard, C., Loriot, Y., Albiges, L., Blanchard, P., Bossi, A., Nenan, S., & Fizazi, K. (2020). Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial. Clinical Genitourinary Cancer, 18(6), 444-451. https://doi.org/10.1016/j.clgc.2020.03.017

@article{f853c3c491c44515b6c4e3b9060499e3,

title = "Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial",

abstract = "Addition of taxane-based chemotherapy to androgen deprivation therapy improved relapse-free survival in men with high-risk localized prostate cancer; however, long-term toxicities are unknown. This longitudinal study of 78 patients from the GETUG-12 randomized trial treated at Gustave Roussy shows that additional chemotherapy with docetaxel and estramustine does not impact the restoration of androgen secretion and related side effects after castration discontinuation.",

keywords = "Cardiovascular events, Erectile dysfunction, Libido, Neoadjuvant chemotherapy, Testosterone",

author = "Cl{\'e}ment Dumont and Giulia Baciarello and Bosset, {Pierre Olivier} and Pernelle Lavaud and Emeline Colomba and Christophe Massard and Yohann Loriot and Laurence Albiges and Pierre Blanchard and Alberto Bossi and Soazig Nenan and Karim Fizazi",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = dec,

day = "1",

doi = "10.1016/j.clgc.2020.03.017",

language = "English",

volume = "18",

pages = "444--451",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

number = "6",

}

Dumont, C, Baciarello, G, Bosset, PO, Lavaud, P, Colomba, E, Massard, C, Loriot, Y, Albiges, L, Blanchard, P, Bossi, A, Nenan, S & Fizazi, K 2020, 'Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial', Clinical Genitourinary Cancer, vol. 18, no. 6, pp. 444-451. https://doi.org/10.1016/j.clgc.2020.03.017

Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial. / Dumont, Clément; Baciarello, Giulia; Bosset, Pierre Olivier et al.
In: Clinical Genitourinary Cancer, Vol. 18, No. 6, 01.12.2020, p. 444-451.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial

AU - Dumont, Clément

AU - Baciarello, Giulia

AU - Bosset, Pierre Olivier

AU - Lavaud, Pernelle

AU - Colomba, Emeline

AU - Massard, Christophe

AU - Loriot, Yohann

AU - Albiges, Laurence

AU - Blanchard, Pierre

AU - Bossi, Alberto

AU - Nenan, Soazig

AU - Fizazi, Karim

PY - 2020/12/1

Y1 - 2020/12/1

N2 - Addition of taxane-based chemotherapy to androgen deprivation therapy improved relapse-free survival in men with high-risk localized prostate cancer; however, long-term toxicities are unknown. This longitudinal study of 78 patients from the GETUG-12 randomized trial treated at Gustave Roussy shows that additional chemotherapy with docetaxel and estramustine does not impact the restoration of androgen secretion and related side effects after castration discontinuation.

AB - Addition of taxane-based chemotherapy to androgen deprivation therapy improved relapse-free survival in men with high-risk localized prostate cancer; however, long-term toxicities are unknown. This longitudinal study of 78 patients from the GETUG-12 randomized trial treated at Gustave Roussy shows that additional chemotherapy with docetaxel and estramustine does not impact the restoration of androgen secretion and related side effects after castration discontinuation.

KW - Cardiovascular events

KW - Erectile dysfunction

KW - Libido

KW - Neoadjuvant chemotherapy

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=85083712802&partnerID=8YFLogxK

U2 - 10.1016/j.clgc.2020.03.017

DO - 10.1016/j.clgc.2020.03.017

M3 - Article

C2 - 32349927

AN - SCOPUS:85083712802

SN - 1558-7673

VL - 18

SP - 444

EP - 451

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

IS - 6

ER -

Dumont C, Baciarello G, Bosset PO, Lavaud P, Colomba E, Massard C et al. Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial. Clinical Genitourinary Cancer. 2020 Dec 1;18(6):444-451. doi: 10.1016/j.clgc.2020.03.017

Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial

Abstract

Keywords

Access to Document

Other files and links

Cite this